• 微細化された粒子で構成され、速やかに崩壊し、滑らかで粘性のある懸濁液となる。
  • 飲みやすい服用液:
    • 苦い薬物の味を隠す
    • 水なしで口の中で素早く溶ける
  • AdvaTab錠剤は、速放性製剤または徐放性製剤と生物学的に同等であることが証明されている。




  • Advatabs®は、低水分の速崩壊性マトリックスに均一に分散されたコーティングされた薬物粒子を組み込んでいる。
  • Formulated for acceptable taste, a disintegration time <30 seconds
  • プッシュスルー・ブリスターパックおよびマルチパッキングコンフィギュレーションに適している。
  • 最大500mgの薬剤充填が可能





Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies

Dr. Srinivasan Shanmugam is involved in the development and expansion of Adare’s pharmaceutical technology portfolio and supports product development, co-development, and tech transfer opportunities. Dr. Shanmugam has a Ph.D. M.S., and a B.S. in Pharmacy. Dr. Shanmugam has more than 20 years of experience in designing and development of conventional, NDDS/alternate, advanced/modified drug delivery systems, and pharmaceutical platform technologies for oral and other routes of administration. His expertise includes enabling technologies for challenging drugs and developing platform technologies. Additionally, his expertise includes patient-centric solutions focusing on pediatric and geriatric populations to achieve dose convenience, flexibility, and precision.  Dr. Shanmugam has published numerous research articles, holds multiple patents, and is a reviewer/editorial member of various prestigious journals. Shanmugam’s recent work focuses on product development solutions for special patient populations like pediatric and geriatric populations.